← Eichor
Study identifier: NCT04799912 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Labor Induction in Low-risk Nulliparous Women at 39 Weeks of Gestation to Reduce Cesarean: A Randomized Trial of Induction Versus Expectant Management in France (FRENCH-ARRIVE)

Condition: Cesarean Section  ·  Sponsor: University Hospital, Bordeaux

PhaseNA
Planned participants4200
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The recent ARRIVE trial conducted in United States of America in 2014-2017 demonstrates that elective induction of labor at 39 weeks for nulliparous women did result in a significantly lower frequency of cesarean delivery with no significant differences of adverse perinatal outcomes. But the expected benefits of elective labor induction at 39 weeks have to be confirmed in other settings outside US before considering routine induction of labor for all low-risk nulliparous women at 39 weeks of gestation worldwide.

This description comes directly from the study's public registry record.

Talk to the study team

Loic Sentilhes, MD, PhD  ·  +33556795579  ·  loic.sentilhes@chu-bordeaux.fr

Hugo Madar, MD  ·  hugo.madar@chu-bordeaux.fr

Always discuss trial participation with your own doctor first.

Locations (1)

CHU de BordeauxBordeaux, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04799912